Understanding how a specific protein affects prostate cancer growth and treatment resistance
Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
['FUNDING_OTHER'] · RESEARCH INST OF FOX CHASE CAN CTR · NIH-11231970
This study is looking at how a specific protein called ERG affects prostate cancer cells, especially those that are important for hormone treatments, to find new ways to make these cancer cells more vulnerable and improve treatment options for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST OF FOX CHASE CAN CTR (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11231970 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the ERG oncoprotein in prostate cancer, particularly how it influences the behavior of luminal cells, which are a key target for hormone therapies. By using advanced mouse models and organoid systems, the study aims to uncover the molecular mechanisms that allow prostate cancer cells to invade and resist treatment. The research also employs genome-wide screening techniques to identify potential vulnerabilities in these cancer cells that could be targeted for new therapies. Insights gained from this work may lead to innovative treatment strategies for patients with prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with prostate cancer, especially those exhibiting luminal histology and resistance to hormone therapy.
Not a fit: Patients with non-prostate cancers or those whose prostate cancer does not exhibit ERG overexpression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with prostate cancer, particularly those who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in cancer, suggesting that this approach may yield valuable insights and potential breakthroughs.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESEARCH INST OF FOX CHASE CAN CTR — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FENG, WEIRAN — RESEARCH INST OF FOX CHASE CAN CTR
- Study coordinator: FENG, WEIRAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer research